Invasive and non-invasive investigations for tamoxifen-induced non-alcoholic steatohepatitis (NASH): The benefit of computed tomography scan guided liver biopsy [8]

Pathology

Volumn 38, Issue 3, 2006, Pages 270-271

  Ahmed, M H ^a   Osman, K A ^a   Osman, M M ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

AMINOTRANSFERASE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; LETTER; LIVER BIOPSY; MONITORING; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PREDICTION;

EID: 33745085818     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020600699201     Document Type: Article

References (8)

1. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330 (7497): 932.
2. Bauditz J, Schmidt HH, Dippe P, Lochs H, Pirlich M. Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid. Am J Gastroenterol 2004; 99: 959-60.
3. Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol 2003; 98: 2348-50.
4. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
5. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-8.
6. Ahmed MH, Byrne CD. Non-alcoholic steatohepatitis. In: Byrne CD, Wild S, editors. Metabolic Syndrome. London: Wiley & Sons, 2005; 279-303.
7. Murata Y, Ogawa Y, Saibara T, et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Oncol Rep 2003; 10: 97-100.
8. Ratziu V, Charlotte F, Heurtier A, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.